The Biden administration announced on Friday the selection of the next 15 prescription drugs that will undergo price negotiations between manufacturers and Medicare, three days before President-elect Donald Trump is set to take office and take over the program.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Education: Trump’s proposals for K-12 schools include having parents elect school principals, cutting federal funding to any school teaching “critical race theory,” ending t

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of unknowns.

Groups representing employers that offer health insurance are gearing up to defend and try to bolster the largest source of health coverage for people under 65 in the U.S.

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.

Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

The Biden administration’s last MA rule is a boon for insurers, though it remains to be seen how the incoming Trump administration might put its stamp on the regulation before it’s finalized this spring.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to<a class="excerpt-read-more" href=" More

Instead, people on Medicare won’t get the two years of continued coverage for telehealth appointments and five years’ for acute hospital at home programs that were in the bill Congress nearly voted into law in December 2024.

The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump administration.